After Hours Gainers:
Companies trading higher in after hours in reaction to earnings/guidance: TRUE +31%, FSLY +20.6%, STMP +18.1%, SIEN +16.1%, AAXN +14.5%, ZG +11.6%, YELP +11.2%, QNST +11.1% (also retains Goldman Sachs for review of strategic alternatives), EB +10.8%, SWCH +10%, CORT +8.7%, FARM +7.7% (also discloses CFO change), PLNT +7.4% (also appoints Jeremy Tucker as Chief Marketing Officer, effective November 20), GPRO +6.6%, GH +6.5%, LGF.A +6.4%, MIME +5.8%, CDAY +5.3% (CFO Arthur Gitajn to retire), BKNG +5.2%, DIS +5.2%, UEPS +5.2%, NET +4.2%, NCR +4.1%, PAR +3.8% (light volume), SWAV +2.9%, AMH +2.5%, MNST +2.4%, AMPH +2.2% (light volume), NLOK +1.4%, MTW +1.3%
Companies trading higher in after hours in reaction to news: CFMS +17.3% (announces FDA clearance of next generation Conformis Hip System), WKHS +10.9% (enters into intellectual property licensing agreement with Lordstown Motors Corp), PRTY +6.5% (modestly rebounding from today's 67% decline, was also downgraded to Market Perform at Telsey Advisory Group), NK +6.4% (announces presentation of results from Phase 2 trial of natural killer cell-based therapeutic in metastatic Merkel cell carcinoma), DB +2.7% (positive mention on CNBC's Fast Money), ZIXI +1.9% (ticking higher; initiated with Outperform at Wedbush; tgt $10)
After Hours Losers:
Companies trading lower in after hours in reaction to earnings/guidance: MED -24.9%, NVEE -22.1%, MOD -19.8%, TDC -18.7% (also names Victor Lund interim CEO following departure of Oliver Ratzesberger), ARLO -13.3%, RGR -12.8%, HEAR -11.2%, CWH -10.4%, TUSK -9.1%, GDOT -8.2%, PEN -8.1%, CTRE -5.9% (light volume), ENLC -5%, UPLD -4.9%, MTD -4.6%, TTD -4.4%, SVMK -4.3%, ALTR -3.9%, PETQ -3.6% (light volume), ATVI -2.2%, LADR -1.9% (light volume), TTWO -1%
Companies trading lower in after hours in reaction to news: ADMS -10.6% (files $200 mln mixed securities shelf offering; reports Q3 results), GPS -7% (names Chairman Robert Fisher to as interim CEO, sees Q3 EPS below consensus), AFMD -6.9% (IND has cleared the required 30-day review by the FDA for a Phase 1/2a clinical trial of AFM24; announces progress on NK cell engager collaboration with Roche Group's Genentech; commences public offering of common shares; size not disclosed), LXRX -6.4% (files $150 mln mixed securities shelf offering), WORK -4.1% (initiated with Underperform at Wedbush; tgt $14)
After Hours Summary: ZG +12%, YELP +11%, BKNG / DIS +5% are higher, while MED -25%, TDC -19% are lower following earnings/guidance